Evidence map›Paper›PMID 32354920›Full record

ReviewIn vivo (Athens, Greece)

Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature.

Francesco Cuccia, Gianluca Mortellaro, Lucia Ognibene, Giuseppe Craparo, Antonio Lo Casto, Giuseppe Ferrera

Open access · diamondAbstract readCase ReportsReview
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Francesco CucciaRadiation Oncology School, University of Palermo, Palermo, Italy f.cuccia1@virgilio.it.
Gianluca MortellaroRadiotherapy Unit, ARNAS Civico Hospital, Palermo, Italy.
Lucia OgnibeneRadiotherapy Unit, San Gaetano Radiotherapy and Nuclear Medicine Center, Palermo, Italy.
Giuseppe CraparoNeuroradiology Unit, ARNAS Civico Hospital, Palermo, Italy.
Antonio Lo CastoRadiation Oncology School, University of Palermo - Section of Radiology - Di.Bi.Med., Palermo, Italy.
Giuseppe FerreraRadiotherapy Unit, ARNAS Civico Hospital, Palermo, Italy.
Azienda di Rilievo Nazionale ed Alta Specializzazione · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMedulloblastoma is a rare tumor of adult age, while it occurs more frequently in children. Given the rarity, there is a lack of evidence for the treatment of recurrent disease. Few data are available about salvage re-irradiation collecting very heterogeneous series. CASE REPORT: A 51-year-old male presented with headache, nausea, double vision, and gait disorders. A contrast-enhanced brain-MRI showed the presence of multifocal medulloblastoma. After surgery, adjuvant craniospinal radiotherapy was performed, chemotherapy was stopped due to toxicity. After 27 months, a new MRI and a Methionine-PET revealed a late pontocerebellar relapse; multidisciplinary board decided for a SBRT treatment. The second course of RT was well tolerated and 14 months later, the patient is alive in good general conditions, with no evidence of disease.

conclusionOur experience supports the use of salvage stereotactic radiotherapy as a safe and effective treatment option.

Indexed as

Re-IrradiationCerebellar NeoplasmsHumansMagnetic Resonance ImagingMaleMedulloblastomaMiddle AgedPositron-Emission TomographySalvage TherapyTreatment OutcomeTumor Burdenadult patientsMedulloblastomare-irradiation

Identifiers

PMID32354920
PMCPMC7279819
OpenAlexW3022524778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.